This article is more than 5 years old. Information may no longer be current.

Alimera reports 13% increase in quarterly revenue

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Alimera Sciences reported an increase in consolidated net revenue of 13% from $9.8 million to $11.1 million in the third quarter of 2018, according to a press release.

Revenue in the U.S. rose 20% from $7.1 million to $8.5 million, while international revenue remained flat at approximately $2.6 million.

The company posted a net loss of $3.5 million compared with a net loss of $5.3 million in 2017’s third quarter. The net income per common share was $0.40 compared with a net loss per common share of $0.08 a year ago.

General and administrative costs increased by $100,000 to $3.4 million, sales and marketing costs decreased from $6 million to $5.5 million, and research, development and medical affairs costs decreased to $2.8 million compared with $5.4 million.